Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ming Jai Liu

Neurology Gilbert, AZ Medical Doctor

NPI 1932211232 CMS profile 617721

1757 E Baseline Rd Ste 105, Gilbert, AZ 85233

Open in the dashboard

General payments

$8,165

472 records reported · program years 2019–2025

Research payments

$29,500

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$8,500 paid to institutions, not to them · program year 2021

Through program year 2025, Ming Jai Liu of Gilbert, AZ is reported in the CMS Open Payments database as having received $8,165 across 472 general payments and $29,500 in research payments paid to them. Separately, studies naming them as principal investigator received $8,500 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $282 12
2024 General $69 3
2023 General $811 41
2022 General $2,828 144
2021 General $2,378 163
2020 General $1,707 103
2020 Research $14,500 1
2019 General $89 6
2019 Research $15,000 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ming Jai Liu
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Ming Jai Liu were reported at $282. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Ming Jai Liu Neurology median Middle half National median
2019 $89 $474 $118–$2,177 $163
2020 $1,707 $367 $82–$2,309 $114
2021 $2,378 $438 $104–$2,547 $132
2022 $2,828 $442 $103–$2,388 $149
2023 $811 $464 $119–$2,312 $160
2024 $69 $468 $119–$2,323 $164
2025 $282 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,320 82 payments
  2. UCB, Inc. $632 39 payments
  3. Novartis Pharmaceuticals Corporation $587 50 payments
  4. Teva Pharmaceuticals USA, Inc. $520 32 payments
  5. Allergan Inc. $500 35 payments
  6. Alexion Pharmaceuticals, Inc. $374 19 payments
  7. Abbott Laboratories $370 8 payments
  8. Amgen Inc. $328 22 payments
  9. ACADIA Pharmaceuticals Inc $326 27 payments
  10. Biogen, Inc. $219 11 payments
  11. Other $2,989 147 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,871 462 payments
  2. Education $211 5 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $83 5 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $581 46 payments
  2. Briviact $452 29 payments
  3. BOTOX $449 29 payments
  4. AIMOVIG $413 31 payments
  5. INFINITY $345 7 payments
  6. KESIMPTA $304 28 payments
  7. NUPLAZID $259 23 payments
  8. DUOPA $244 13 payments
  9. QULIPTA $238 11 payments
  10. Soliris $213 11 payments
  11. Other $4,901 260 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. ACADIA Pharmaceuticals Inc $29,500 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

31

Median for Neurology: 833

Drug cost

$1,017

Median for Neurology: $202,670

Branded share of claims

0%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Levetiracetam Generic 14 $559
Donepezil Hcl Generic 17 $458

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
  • Novartis Pharmaceuticals Corporation $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

475 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record